Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H33N5O2 |
| Molecular Weight | 459.5832 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC(CC1)N2CCN(CC2)C(=O)[C@H](NC(=O)C3=CC4=C(C=CN4)C=C3)C5=CC=CC=C5
InChI
InChIKey=VYNKVNDKAOGAAQ-RUZDIDTESA-N
InChI=1S/C27H33N5O2/c1-30-13-10-23(11-14-30)31-15-17-32(18-16-31)27(34)25(21-5-3-2-4-6-21)29-26(33)22-8-7-20-9-12-28-24(20)19-22/h2-9,12,19,23,25,28H,10-11,13-18H2,1H3,(H,29,33)/t25-/m1/s1
| Molecular Formula | C27H33N5O2 |
| Molecular Weight | 459.5832 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:14:55 GMT 2025
by
admin
on
Mon Mar 31 22:14:55 GMT 2025
|
| Record UNII |
TSA990HP1K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB05713
Created by
admin on Mon Mar 31 22:14:55 GMT 2025 , Edited by admin on Mon Mar 31 22:14:55 GMT 2025
|
PRIMARY | |||
|
313489-71-3
Created by
admin on Mon Mar 31 22:14:55 GMT 2025 , Edited by admin on Mon Mar 31 22:14:55 GMT 2025
|
PRIMARY | |||
|
TSA990HP1K
Created by
admin on Mon Mar 31 22:14:55 GMT 2025 , Edited by admin on Mon Mar 31 22:14:55 GMT 2025
|
PRIMARY | |||
|
DTXSID00953385
Created by
admin on Mon Mar 31 22:14:55 GMT 2025 , Edited by admin on Mon Mar 31 22:14:55 GMT 2025
|
PRIMARY | |||
|
9939865
Created by
admin on Mon Mar 31 22:14:55 GMT 2025 , Edited by admin on Mon Mar 31 22:14:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
Exhibits 1000-fold greater selectivity
relative to inhibition of other serine proteases.
Ki
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
||||
| Biological Half-life | PHARMACOKINETIC |
|